Gregory A. Lizee, Ph.D.
Affiliations: | 2000 | University of British Columbia, Vancouver, Vancouver, BC, Canada |
Area:
Immunology, Molecular BiologyGoogle:
"Gregory Lizee"Mean distance: 26716.5
Parents
Sign in to add mentor| Wilfred A. Jefferies | grad student | 2000 | UBC | |
| (MHC class I cytoplasmic domain: Defining a role for conserved amino acid residues in class I expression, trafficking, and antigen presentation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jin Y, Miyama T, Brown A, et al. (2024) Tsyn-seq: a T cell synapse-based antigen identification platform. Cancer Immunology Research |
| Chaudhri A, Lizee G, Hwu P, et al. (2024) Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment. Cancer Research |
| Chaudhri A, Bu X, Wang Y, et al. (2023) The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy. Frontiers in Immunology. 14: 1237715 |
| Hall-Swan S, Slone J, Rigo MM, et al. (2023) PepSim: T-cell cross-reactivity prediction via comparison of peptide sequence and peptide-HLA structure. Frontiers in Immunology. 14: 1108303 |
| Liang S, Jiang X, Chiu Y, et al. (2023) An interpretable ML model to characterize patient-specific HLA-I antigen presentation. Biorxiv : the Preprint Server For Biology |
| Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 40: 509-523.e6 |
| Sun Y, Li F, Sonnemann H, et al. (2021) Evolution of CD8 T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells. 10 |
| Li F, Deng L, Jackson KR, et al. (2021) Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. Journal For Immunotherapy of Cancer. 9 |
| Saberian C, Amaria RN, Najjar AM, et al. (2021) Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Journal For Immunotherapy of Cancer. 9 |
| Yoshihama S, Cho SX, Yeung J, et al. (2021) NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Scientific Reports. 11: 3258 |